Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16811 | 0.93 | HSD11B1 (0.31) | HSD11B1 | |
| SCHEMBL23860 | 0.87 | HSD11B1 (0.34) | HSD11B1 | |
| SCHEMBL18340 | 0.86 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL16249 | 0.85 | GCK (0.31) | — | |
| SCHEMBL17936 | 0.85 | HSD11B1 (0.31) | HSD11B1 | |
| SCHEMBL17020 | 0.84 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL18291 | 0.83 | HSD11B1 (0.39) | HSD11B1 | |
| SCHEMBL18009 | 0.83 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL16912 | 0.82 | HSD11B1 (0.34) | HSD11B1 | |
| SCHEMBL16862 | 0.82 | HSD11B1 (0.31) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609081-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |